The investment was led by Blackfinch Ventures alongside Mercia to support platform upgrades and team expansion.
"With hybrid working here to stay, companies need the right technology to manage and motivate teams in different locations. StaffCircle is helping an ever-increasing number of organisations to keep their employees connected and improve productivity. We are delighted to have continued support from our existing investors. The latest funding round will help us to build momentum and take the company to the next level."
The funding follows prior support from Maven and will establish a physical presence in Austin, Texas.
"In the four years we have worked with the senior management team at MirrorWeb we have been impressed by their ambition, the progress they have made in growing revenues, and the traction the Company’s novel technology has had within the market. MirrorWeb is well positioned to continue that growth, capitalising on the rising demand from organisations to have secure digital records of all electronic communications to meet their compliance and regulatory obligations. We are delighted to be providing the follow-on capital MirrorWeb requires to support its expansion into the lucrative US market."
The Series A round will fund the continued development of the company platform for hard-to-drug targets.
"We are advancing this technology and its application to the hit discovery, hit-to-lead and lead optimization processes of small molecule drug discovery."
Octopus Ventures led the Series A round to support machine learning research and language expansion.
"People retain up to 70% more information when watching videos dubbed in their native language. With truly emotive cross-lingual AI dubbing, we can tackle all forms of content, making video and audio more accessible and enjoyable for everyone. This funding will allow us to double down on our promising research and break into new content categories."
The funding round was led by Archangels to support human trials of the BioCaptis device.
"BIOCAPTIVA is at the forefront of developing technology to transform liquid biopsy testing in cancer management. We are pleased to have raised these additional funds as the company enters its next stage of development, with the BioCaptis beginning its first in human trials. These trials will allow us to generate important data before the end of 2022. This will be a key step before starting regulatory trials in 2023 as we move towards our goal of unleashing the full potential of liquid biopsy in cancer management to improve patient outcomes."
